Head-To-Head Analysis: Sandoz Group (OTCMKTS:SDZNY) vs. Daiichi Sankyo (OTCMKTS:DSNKY)

Sandoz Group (OTCMKTS:SDZNY) and Daiichi Sankyo (OTCMKTS:DSNKY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Earnings & Valuation

This table compares Sandoz Group and Daiichi Sankyo”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$10.36 billion	3.10	$1.00 million	N/A	N/A
Daiichi Sankyo	$12.39 billion	3.27	$1.95 billion	$1.06	20.16

Daiichi Sankyo has higher revenue and earnings than Sandoz Group.

Analyst Recommendations

This is a summary of current recommendations for Sandoz Group and Daiichi Sankyo, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	2	0	1	2.67
Daiichi Sankyo	1	0	0	1	2.50

Insider and Institutional Ownership

0.1% of Sandoz Group shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Sandoz Group and Daiichi Sankyo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Daiichi Sankyo	15.40%	18.39%	8.57%

Dividends

Sandoz Group pays an annual dividend of $0.44 per share and has a dividend yield of 0.6%. Daiichi Sankyo pays an annual dividend of $0.36 per share and has a dividend yield of 1.7%. Daiichi Sankyo pays out 34.0% of its earnings in the form of a dividend.

Summary

Daiichi Sankyo beats Sandoz Group on 7 of the 10 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.